Cited by 144Cutaneous Melanoma Detection and Managementmelanin and skin pigmentationAI in cancer detection

The DOI matches its Crossref record; 82 of the 88 references it cites were found in a registry or an index; none of the 8 sources its claims cite is checked for support yet.

Smartphone applications for triaging adults with skin lesions that are suspicious for melanoma

Open access

Abstract

BACKGROUND: Melanoma accounts for a small proportion of all skin cancer cases but is responsible for most skin cancer-related deaths. Early detection and treatment can improve survival. Smartphone applications are readily accessible and potentially offer an instant risk assessment of the likelihood of malignancy so that the right people seek further medical attention from a clinician for more detailed assessment of the lesion. There is, however, a risk that melanomas will be missed and treatment delayed if the application reassures the user that their lesion is low risk. OBJECTIVES: To assess the diagnostic accuracy of smartphone applications to rule out cutaneous invasive melanoma and atypical intraepidermal melanocytic variants in adults with concerns about suspicious skin lesions. SEARCH METHODS: We undertook a comprehensive search of the following databases from inception to August 2016: Cochrane Central Register of Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles. SELECTION CRITERIA: Studies of any design evaluating smartphone applications intended for use by individuals in a community setting who have lesions that might be suspicious for melanoma or atypical intraepidermal melanocytic variants versus a reference standard of histological confirmation or clinical follow-up and expert opinion. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on QUADAS-2). Due to scarcity of data and poor quality of studies, we did not perform a meta-analysis for this review. For illustrative purposes, we plotted estimates of sensitivity and specificity on coupled forest plots for each application under consideration. MAIN RESULTS: This review reports on two cohorts of lesions published in two studies. Both studies were at high risk of bias from selective participant recruitment and high rates of non-evaluable images. Concerns about applicability of findings were high due to inclusion only of lesions already selected for excision in a dermatology clinic setting, and image acquisition by clinicians rather than by smartphone app users.We report data for five mobile phone applications and 332 suspicious skin lesions with 86 melanomas across the two studies. Across the four artificial intelligence-based applications that classified lesion images (photographs) as melanomas (one application) or as high risk or 'problematic' lesions (three applications) using a pre-programmed algorithm, sensitivities ranged from 7% (95% CI 2% to 16%) to 73% (95% CI 52% to 88%) and specificities from 37% (95% CI 29% to 46%) to 94% (95% CI 87% to 97%). The single application using store-and-forward review of lesion images by a dermatologist had a sensitivity of 98% (95% CI 90% to 100%) and specificity of 30% (95% CI 22% to 40%).The number of test failures (lesion images analysed by the applications but classed as 'unevaluable' and excluded by the study authors) ranged from 3 to 31 (or 2% to 18% of lesions analysed). The store-and-forward application had one of the highest rates of test failure (15%). At least one melanoma was classed as unevaluable in three of the four application evaluations. AUTHORS' CONCLUSIONS: Smartphone applications using artificial intelligence-based analysis have not yet demonstrated sufficient promise in terms of accuracy, and they are associated with a high likelihood of missing melanomas. Applications based on store-and-forward images could have a potential role in the timely presentation of people with potentially malignant lesions by facilitating active self-management health practices and early engagement of those with suspicious skin lesions; however, they may incur a significant increase in resource and workload. Given the paucity of evidence and low methodological quality of existing studies, it is not possible to draw any implications for practice. Nevertheless, this is a rapidly advancing field, and new and better applications with robust reporting of studies could change these conclusions substantially.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This Cochrane review found only two eligible studies (332 lesions, 86 melanomas) and could not produce summary estimates, so the accuracy of smartphone apps for melanoma triage remains unreliable. Automated apps missed a substantial proportion of melanomas, while a store-and-forward dermatologist-review app had high sensitivity but low specificity and frequent test failures.

Key findings

  • Across four artificial intelligence-based apps, sensitivity ranged from 7% (95% CI 2% to 16%) to 73% (95% CI 52% to 88%) and specificity from 37% (95% CI 29% to 46%) to 94% (95% CI 87% to 97%); with melanoma prevalence of 18% to 37%, the number of melanomas missed was 7 to 55.
  • The single store-and-forward app had sensitivity of 98% (95% CI 90% to 100%) and specificity of 30% (95% CI 22% to 40%); the dermatologist missed one melanoma, but 6/60 melanomas assessed were classed as unevaluable.
  • Test failures/unevaluable lesions ranged from 3 to 31 (2% to 18% of lesions analysed); the store-and-forward app had one of the highest test-failure rates at 15%.
  • In Maier 2015, face-to-face dermatologist diagnosis of the same lesions had sensitivity of 85% (95% CI 65% to 96%) and specificity of 97% (95% CI 93% to 99%), though the review notes these data are not directly comparable to the app’s output.

Methods

  • Systematic review of diagnostic test accuracy studies; searched MEDLINE, Embase, CENTRAL, CINAHL and other sources to August 2016, including adults with pigmented or suspicious skin lesions, smartphone apps intended for public use, and histology or acceptable reference standards.
  • Included two studies (Wolf 2013, USA; Maier 2015, Germany) providing six datasets; 332 lesions were successfully analysed, including 86 melanomas; the unit of analysis was the lesion.
  • Due to scarcity and poor quality of data, no meta-analysis was performed; results were plotted on coupled forest plots, and risk of bias/applicability was assessed with a tailored QUADAS-2 tool.

Limitations

  • The paper states the small number and poor quality of included studies reduce reliability, with high risk of bias for patient selection (selective inclusion; case-control design in Wolf 2013) and high applicability concerns because participants were secondary-care lesions scheduled for excision and photographs were taken by doctors rather than smartphone users.
  • The paper states test failures/unevaluable images were excluded (2% to 18% of lesions), likely overestimating sensitivity; studies did not report key patient information such as age and gender, and melanoma prevalence was 18% and 35%, much higher than in community settings.
  • Evident from the text: no meta-analysis, heterogeneity investigation, sensitivity analyses, or publication-bias assessment was possible, and only two studies were included, so conclusions could change substantially with new higher-quality studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/14651858.cd013192

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 8 cited sources checked · 0 supported · 0 flagged

Show all 63 claims

  • It may state two separate claims as one. 62
  • Probably not a substantial claim. 81
  • The quote only partly states this claim. 1
126 of 126
  • The paper relies on this without support.

    The prevalence of melanoma in the included studies is much higher than that observed in community settings.

    “The percentage of people with a final diagnosis of melanoma was 18% and 35%, much higher than that observed in community settings.”
  • The paper relies on this without support.

    Smartphone applications for skin lesion triage are intended to be used by members of the public in a community setting.

    “rather than the community setting where these applications are intended to be used”
    “the intended users of the smartphone applications (i.e.members of the public)”
  • The authors state this as an assumption.

    The review assumes that the 'two-point differences cases' excluded in Maier 2015 are lesions whose results fall in non-consecutive risk classes.

    “we assume this to mean lesions with results in non-consecutive risk classes, e.g. 1 high risk and 2 low risk”
  • The authors state this as an assumption.

    The review assumes that the interval between the index test and the reference standard in Maier 2015 was less than one month.

    “assume it is < 1 month as images of the lesions were taken prior to excision”
  • The paper relies on this without support.

    In routine practice, the clinical diagnosis is included on pathology request forms and histopathologists use it to help interpret the pathology.

    “It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation.”
  • The paper relies on this without support.

    Blinded reading of the histopathology reference standard is not standard practice.

    “blinded interpretation of the histopathology reference standard is not normal practice”
    “histopathology interpretation is usually conducted with knowledge of the clinical diagnosis (from visual inspection or dermoscopy or both).”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Figure 8 gives the dermatologist test the wrong decision threshold

    Minor

    The Figure 8 caption labels the face-to-face diagnosis as high risk versus medium/low risk, but the data table identifies its decision as melanoma versus not melanoma.

  • Maier melanoma count changes from 40 to 60

    Minor

    The table footnote says the original Maier sample of 195 lesions contained 60 melanomas, whereas the study characteristics give 40 melanomas for that same sample.

  • Wolf exclusions are described as both common and uncommon lesions

    Minor

    The methodological-quality discussion says Wolf excluded common lesions, whereas the results section says it excluded uncommon lesions. Both passages also mention equivocal diagnoses, making the difference in lesion frequency explicit.

  • Six Wolf lesions are unaccounted for in App 3 results

    Minor

    The table gives 188 Wolf lesions, but App 3 has 170 successfully assessed lesions and 12 unevaluable lesions, totaling only 182. The other six lesions are not accounted for in the reported App 3 flow.

    Reported 188 · recomputed 182

4 of 4

Citations

Cites

Flagged first, then by citations

6 of the 88 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Braunmühl, 2015, Smartphone apps for skin cancer diagnosis? The Munich study, Kosmetische Medizin, 36, 152
  2. Australian Cancer Database, 2017, Melanoma of the skin for Australia (ICD10 C43)
  3. Ndegwa, 2010, Teledermatology services: rapid review of diagnostic, clinical management, and economic outcomes

Cited by

Sorted by citations

See all 144

Metadata

Authors
Chuchu, N., Takwoingi, Y., Dinnes, J., Matin, R. N., Bassett, O., Moreau, J. F., Bayliss, S. E., Davenport, C., Godfrey, K., O'Connell, S., Jain, A., Walter, F. M., Deeks, J. J., Williams, H. C., & Cochrane Skin Cancer Diagnostic Test Accuracy Group
Affiliations
  • University of Birmingham (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Churchill Hospital (GB)
  • Addenbrooke's Hospital (GB)
  • University of Pittsburgh Medical Center (US)
  • University of Nottingham (GB)
  • Cardiff and Vale University Health Board (GB)
  • Imperial College Healthcare NHS Trust (GB)
  • University of Cambridge (GB)
Corresponding author
Dinnes, Jacqueline
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2018-12-04
Volume
2018
Issue
12
Pages
CD013192-CD013192
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2886914906
Cited by
144
References
88
Citations by year
2026: 4 · 2025: 10 · 2024: 16 · 2023: 18 · 2022: 18 · 2021: 29 · 2020: 26 · 2019: 15 · 2018: 7
FWCI
2.02
Type
journal article
Language
en
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • Melanoma Research Alliance
  • National Institute for Health and Care Research (13/89/15, NIHR-CS-012-030)
  • British Association of Dermatologists
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › melanin and skin pigmentation
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
Keywords
melanoma, mobile application, mobile health, skin lesions, artificial intelligence, diagnostic accuracy, sensitivity and specificity, early detection of skin cancer, image classification, histopathological confirmation, delayed diagnosis, quality of evidence, risk of bias, applicability, cost-effectiveness
MeSH terms
Smartphone, Cutaneous Malignant Melanoma, Adult, Algorithms, Diagnostic Errors, Humans, Melanoma, Sensitivity and Specificity, Skin Neoplasms, Triage, Early Detection of Cancer, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review